Company Focus
Novo Nordisk
Latest Novo Nordisk News
Pharmaceutical
It has been a year since the launch of Zepbound (tirzepatide) for obesity, and US pharma major Eli Lilly’s competition with Denmark’s Novo Nordisk continues. 31 December 2024
Related News
Insights
Company Spotlight
Acadia Pharmaceuticals (Nasdaq: ACAD) is a leading pharmaceutical company with a focus on bringing life-changing therapies to patients suffering from CNS diseases.
Latest News & Features of interest to Novo Nordisk
Biotechnology
Privately-held Muna Therapeutics, a Danish biotech focused on neurodegenerative diseases, has announced a research alliance with UK pharma major GSK to identify and validate novel drug targets for the treatment of Alzheimer’s disease. 5 December 2024
Biotechnology
The global precision medicine market is projected to expand significantly, with an estimated growth of $66 billion between 2024 and 2028, according to Technavio. 5 December 2024
Biotechnology
US CNS specialist Relmada Therapeutics lost 77% of its stock market value on Wednesday, dropping its share price well below $1. 5 December 2024
Pharmaceutical
US drugmaker Eli Lilly enjoyed a good day on the obesity front on Wednesday, with the news that its GLP-1 receptor agonist tirzepatide - branded as Wegovy and Mounjaro - outscored its main rival from Novo Nordisk in a Phase IIIb trial. 5 December 2024
Biotechnology
Privately-held Dewpoint Therapeutics, a Boston, USA, biotech developing therapeutics by targeting biomolecular condensates, has entered into a strategic research collaboration with Japan’s Mitsubishi Tanabe Pharma Corporation (MTPC). 4 December 2024
Pharmaceutical
The battle between the two front runners in the vast weight loss treatment market took a turn today, when US pharma major Eli Lilly released top-line results from the SURMOUNT-5 Phase IIIb open-label randomized clinical trial. 4 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
Danish drug developer Antag Therapeutics, which is pioneering novel treatments for obesity, today announced the closing of an 80 million euros ($83.8 million) Series A financing. 4 December 2024
Pharmaceutical
Japanese pharma major Takeda has agreed an exclusive licensing agreement with US pharma Keros Therapeutics to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. 3 December 2024
Biotechnology
California’s XOMA Royalty Corporation has announced that it now owns an economic interest in seralutinib, a Phase III asset being studied in pulmonary arterial hypertension (PAH), through its $20 million acquisition of Pulmokine, a privately-held company. 3 December 2024
Latest In Brief for Novo Nordisk
Biotechnology
The Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for the treatment of early Alzheimer’s disease (AD). 5 December 2024
Latest Related Ones To Watch News
Venture capital firm BC Partners has entered into an agreement under which the private equity business at Goldman Sachs Alternatives will acquire a majority stake in Netherlands-based Synthon, from funds advised by BC Partners. 17 December 2024
16 December 2024
7 December 2024
3 December 2024
28 November 2024
26 November 2024
21 November 2024
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze